Corporate Overview

History/Financing

In late 1997, Dr. Garfield Royer, a Ph.D. biochemist with both academic and industrial experience, founded Royer Biomedical, Inc. originally as Buford Biomedical, Inc., and a patent application covering resorbable matrix, developed by Dr. Royer, was filed (issued 1998). The board of directors officially changed the name of the company to Royer Biomedical, Inc. in December 2000.

Dr. Royer and several private investors provided start-up financing. In 1997, awards from the State of Maryland Department of Business and Economic Development (DBED) induced a move to Frederick, Maryland. A private stock offering closed in March 2000, and a supplemental offering in March 2001. An offering of convertible notes with warrants is currently open. To date, Royer Biomedical, Inc. has raised a total of approximately $3.5 million.

Corporate Strategy

Royer Biomedical, Inc.'s product commercialization strategy is two-fold:

(1) commercialization by RBI (U.S. only) of selected products; and
(2) to form corporate partnerships with established pharmaceutical companies for marketing of our products outside the U.S.

In the U.S. we strive to advance human health products ourselves through the regulatory process as far as possible before a) seeking major outsides financing or b) entering into a marketing relationship with a partner.